Active Ingredient History
Icotinib is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use in China as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 4)
Adenocarcinoma of Lung (Phase 2)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 2)
Bronchial Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Epidermal Growth Factor (Phase 2)
Esophageal Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 2)
Lung Neoplasms (Phase 4)
Mutation (Phase 3)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neoplasms, Second Primary (Phase 4)
Neurofibromatosis 2 (Phase 2)
Neuroma, Acoustic (Phase 2)
Pancreatic Neoplasms (Phase 1)
Psoriasis (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue